CVC is utilising a well-researched technology originally developed at Massey University in Palmerston North, New Zealand. The technology enables the efficient production of tiny biobeads that are coated in whatever protein or polypeptide one chooses. In our case, we will coat these biobeads in proteins and polypeptides that occur in the SARS-Cov-2 virus. The biobeads and protein coating are simultaneously manufactured inside bacteria which is a very efficient method of production.

Round biobeads that have formed inside a bacterium

The system has the capability to attach most proteins to the surface of the biobeads. In the case of our vaccine, we intend to place two elements on the surface of the biobeads. One will be from part of the virus protein that attaches to human cells (technically, the receptor binding domain of the S or spike protein). It is expected that this will induce antibodies to the virus, including neutralising antibodies. The other will be a string of specific parts of various virus proteins (T cell epitopes) that is expected to induce a cytotoxic immune response. The two will be manufactured in separate batches and then combined.

The main aspects of the biobeads technology are: